Thomas A Burke

Summary

Country: USA

Publications

  1. ncbi Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice
    Thomas A Burke
    Epidemiology Department, University of Medicine and Dentistry of New Jersey UMDNJ, School of Public Health, Piscataway, New Jersey, USA
    J Hypertens 24:1193-200. 2006
  2. ncbi The effect of antihypertensive drugs and drug combinations on the incidence of new-onset type-2 diabetes mellitus
    Thomas A Burke
    Epidemiology Department, School of Public Health, University of Medicine and Dentistry of New Jersey UMDNJ, NJ, USA
    Pharmacoepidemiol Drug Saf 16:979-87. 2007
  3. ncbi Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice
    Sean Z Zhao
    Pharmacia Corporation, Peapack, New Jersey, USA
    Am J Manag Care 8:S392-400. 2002
  4. ncbi Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors
    Sean Z Zhao
    Pharmacia Corporation, Peapack, New Jersey, USA
    Am J Manag Care 8:S401-13. 2002
  5. ncbi Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors
    Sean Z Zhao
    Pharmacia Corporation, Peapack, New Jersey, USA
    Am J Manag Care 8:S414-27. 2002
  6. ncbi The impact of losartan on the lifetime incidence of ESRD and costs in Mexico
    Armando Arredondo
    National Institute of Public Health, Cuernavaca, Mexico
    Rev Invest Clin 57:399-405. 2005
  7. ncbi Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension
    Jane T Osterhaus
    Wasatch Health Outcomes, Park City, Utah 84060, USA
    Clin Ther 24:969-89. 2002
  8. ncbi Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective
    Wong Kok Seng
    Department of Nephrology, Singapore General Hospital, Singapore
    Nephrology (Carlton) 10:520-4. 2005
  9. ncbi Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial
    Bengt Jonsson
    Stockholm School of Economics, Stockholm, Sweden
    J Hypertens 23:1425-31. 2005
  10. ncbi A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population
    Russell V Becker
    Ovation Research Group, Highland Park, Illinois, USA
    Clin Ther 25:647-62. 2003

Collaborators

Detail Information

Publications11

  1. ncbi Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice
    Thomas A Burke
    Epidemiology Department, University of Medicine and Dentistry of New Jersey UMDNJ, School of Public Health, Piscataway, New Jersey, USA
    J Hypertens 24:1193-200. 2006
    ..To evaluate antihypertensive drug discontinuation among newly diagnosed hypertensive patients...
  2. ncbi The effect of antihypertensive drugs and drug combinations on the incidence of new-onset type-2 diabetes mellitus
    Thomas A Burke
    Epidemiology Department, School of Public Health, University of Medicine and Dentistry of New Jersey UMDNJ, NJ, USA
    Pharmacoepidemiol Drug Saf 16:979-87. 2007
    ..To evaluate the effect of antihypertensive drugs on new-onset type-2 diabetes...
  3. ncbi Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice
    Sean Z Zhao
    Pharmacia Corporation, Peapack, New Jersey, USA
    Am J Manag Care 8:S392-400. 2002
    ....
  4. ncbi Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors
    Sean Z Zhao
    Pharmacia Corporation, Peapack, New Jersey, USA
    Am J Manag Care 8:S401-13. 2002
    ....
  5. ncbi Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors
    Sean Z Zhao
    Pharmacia Corporation, Peapack, New Jersey, USA
    Am J Manag Care 8:S414-27. 2002
    ..The higher heart failure costs of rofecoxib were attributable to the higher incidence of patients with inpatient and outpatient heart failure claims relative to celecoxib and nonspecific NSAID populations being compared...
  6. ncbi The impact of losartan on the lifetime incidence of ESRD and costs in Mexico
    Armando Arredondo
    National Institute of Public Health, Cuernavaca, Mexico
    Rev Invest Clin 57:399-405. 2005
    ..The objective of this study was to project the effect of losartan compared to placebo on the lifetime incidence of ESRD and associated costs from a third-party payer perspective in Mexico...
  7. ncbi Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension
    Jane T Osterhaus
    Wasatch Health Outcomes, Park City, Utah 84060, USA
    Clin Ther 24:969-89. 2002
    ..The addition of a nonsteroidal anti-inflammatory drug to the regimen of a patient with treated hypertension can cause a destabilization of blood pressure...
  8. ncbi Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective
    Wong Kok Seng
    Department of Nephrology, Singapore General Hospital, Singapore
    Nephrology (Carlton) 10:520-4. 2005
    ..CONCLUSION: Treatment with losartan in patients with type 2 diabetic nephropathy not only reduced the incidence of ESRD among Asian patients, but resulted in direct medical cost savings in countries or regions representing Asia...
  9. ncbi Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial
    Bengt Jonsson
    Stockholm School of Economics, Stockholm, Sweden
    J Hypertens 23:1425-31. 2005
    ..Evaluate the cost effectiveness of losartan compared with atenolol from a Swedish national health system perspective...
  10. ncbi A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population
    Russell V Becker
    Ovation Research Group, Highland Park, Illinois, USA
    Clin Ther 25:647-62. 2003
    ....
  11. ncbi Dosage, titration, and gaps in treatment with extended release niacin in clinical practice
    Sachin J Kamal-Bahl
    Merck and Co Inc, West Point, PA, USA
    Curr Med Res Opin 24:1817-21. 2008
    ..To examine the dosage, titration patterns, and gaps in treatment of newly-initiated ER niacin in clinical practice...